Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

3.4K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.4K
iPS Cell Differentiation01:22

iPS Cell Differentiation

3.0K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.0K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.6K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.6K
Chromatin Modification in iPS Cells01:32

Chromatin Modification in iPS Cells

2.1K
Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
2.1K
MicroRNA Expression Profiles of Human iPS Cells, Retinal Pigment Epithelium Derived From iPS, and Fetal Retinal Pigment Epithelium10:19

MicroRNA Expression Profiles of Human iPS Cells, Retinal Pigment Epithelium Derived From iPS, and Fetal Retinal Pigment Epithelium

11.8K
The microRNA (miRNA) profiles of human induced-pluripotent stem (iPS) cells, retinal pigment epithelium (RPE) derived from human induced-pluripotent stem (iPS) cells (iPS-RPE), and fetal RPE, were compared.
11.8K
IP-FCM: Immunoprecipitation Detected by Flow Cytometry12:17

IP-FCM: Immunoprecipitation Detected by Flow Cytometry

17.9K
The IP-FCM method is presented, which allows a sensitive, robust, biochemical assessment of native protein-protein interactions, without requiring genetic engineering or large sample...
17.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

eIF4G2-mediated selective translation of chromatin regulators safeguards adult intestinal stem cell identity and differentiation.

Cell stem cell·2026
Same author

Emergency Nurses' Comprehensive process of surrogate decision Support: Reanalysis of qualitative data Using a grounded theory.

International emergency nursing·2026
Same author

Emergency nurses' roles in supporting surrogate decision-making through remote family meetings: Insights from COVID-19 visitation restrictions.

International emergency nursing·2025
Same author

A first-in-human clinical study of an allogenic iPSC-derived corneal endothelial cell substitute transplantation for bullous keratopathy.

Cell reports. Medicine·2025
Same author

Self-compassion in patients undergoing haemodialysis: A qualitative study.

Journal of renal care·2024
Same author

Complete suspension culture of human induced pluripotent stem cells supplemented with suppressors of spontaneous differentiation.

eLife·2024

Related Experiment Video

Updated: Jan 19, 2026

MicroRNA Expression Profiles of Human iPS Cells, Retinal Pigment Epithelium Derived From iPS, and Fetal Retinal Pigment Epithelium
10:19

MicroRNA Expression Profiles of Human iPS Cells, Retinal Pigment Epithelium Derived From iPS, and Fetal Retinal Pigment Epithelium

Published on: June 24, 2014

11.8K

Overview: an iPS cell stock at CiRA.

Masafumi Umekage1, Yoshiko Sato1, Naoko Takasu1

  • 1Department of Fundamental Cell Technology, Center of iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507 Japan.

Inflammation and Regeneration
|September 10, 2019
PubMed
Summary

This study establishes a safe induced pluripotent stem cell (iPSC) stock for regenerative medicine. HLA homozygous iPSCs from healthy donors minimize immune rejection, advancing disease treatment options.

Keywords:
Clinical-gradeHLARegenerative medicineStockiPS cells

More Related Videos

EPS and iPS Cells in Disease Research
01:21

EPS and iPS Cells in Disease Research

3.4K
IP-FCM: Immunoprecipitation Detected by Flow Cytometry
12:17

IP-FCM: Immunoprecipitation Detected by Flow Cytometry

Published on: December 2, 2010

17.9K

Related Experiment Videos

Last Updated: Jan 19, 2026

MicroRNA Expression Profiles of Human iPS Cells, Retinal Pigment Epithelium Derived From iPS, and Fetal Retinal Pigment Epithelium
10:19

MicroRNA Expression Profiles of Human iPS Cells, Retinal Pigment Epithelium Derived From iPS, and Fetal Retinal Pigment Epithelium

Published on: June 24, 2014

11.8K
EPS and iPS Cells in Disease Research
01:21

EPS and iPS Cells in Disease Research

3.4K
IP-FCM: Immunoprecipitation Detected by Flow Cytometry
12:17

IP-FCM: Immunoprecipitation Detected by Flow Cytometry

Published on: December 2, 2010

17.9K

Area of Science:

  • Stem Cell Biology
  • Regenerative Medicine
  • Immunology

Background:

  • Induced pluripotent stem cells (iPSCs) offer potential for treating diseases lacking current effective therapies.
  • Regenerative medicine aims to use iPSCs to generate various cell types for therapeutic applications.
  • Minimizing immune rejection is crucial for the success of cell-based therapies.

Purpose of the Study:

  • To establish a safe and effective induced pluripotent stem cell (iPSC) stock for regenerative medicine.
  • To minimize immune rejection in cell transplantation by utilizing HLA homozygous donors.
  • To create an iPSC stock optimized for the Japanese population and suitable for global distribution.

Main Methods:

  • Recruiting healthy, consenting donors with HLA-type homozygous profiles.
  • Deriving iPSCs from peripheral blood mononuclear cells or umbilical cord blood.
  • Manufacturing iPSC stock at a dedicated Cell Processing Center (CPC).

Main Results:

  • Developed an iPSC stock from 5 donors, comprising 21 clones.
  • The iPSC stock is HLA homozygous, aiming to reduce immune rejection.
  • Began offering the iPSC stock for regenerative medicine applications in August 2015.

Conclusions:

  • The established HLA homozygous iPSC stock is a valuable resource for regenerative medicine.
  • This resource has the potential to advance treatments for various diseases by minimizing immune complications.
  • The iPSC stock is available for domestic and international medical institutions and companies.